Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  DeNardo, Gerald L ^a,e   DeNardo, Sally J ^a   Peterson, James J ^b   Miers, Laird A ^a   Lam, Kit S ^a   Hartmann Siantar, Christine ^c   Lamborn, Kathleen R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 IMINOTHIOLANE 1 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID MONOCLONAL ANTIBODY CHL6 Y 90; 2 IMINOTHIOLANE 2 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID MONOCLONAL ANTIBODY LYM 1 IN 111; 2 IMINOTHIOLANE 2 [4 (BROMOACETAMINO)BENZYL] 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID MONOCLONAL ANTIBODY CHL6 (1,4,7,10 TETRAAZACYCLODODECANE) 1,4,7,10 TETRAACETIC ACID IN 111; ANTIBODY CONJUGATE; CATHEPSIN; CATHEPSIN B; CATHEPSIN D; GLYCYLGLYCYLGLYCYLPHENYLALANINE MONOCLONAL ANTIBODY CHL6 (1,4,7,10 TETRAAZACYCLODODECANE) 1,4,7,10 TETRAACETIC ACID IN 111; GLYCYLGLYCYLGLYCYLPHENYLALANINE MONOCLONAL ANTIBODY CHL6 (1,4,7,10 TETRAAZACYCLODODECANE) 1,4,7,10 TETRAACETIC ACID Y 90; GLYCYLPHENYLALANYLGLUTAMINYLGLYCYLVALYLGLUTAMINYLPHENYLALANYLALANYLGLYCYLPH ENYLALANINE MONOCLONAL ANTIBODY LYM 1 (1,4,7,10 TETRAAZACYCLODODECANE) 1,4,7,10 TETRAACETIC ACID IN 111; GLYCYLPHENYLALANYLGLYCYLSERYLTHREONYLPHENYLALANYLPHENYLALANYLALANYLGLYCYLPH ENYLALANINE MONOCLONAL ANTIBODY LYM 1 (1,4,7,10 TETRAAZACYCLODODECANE) 1,4,7,10 TETRAACETIC ACID IN 111; GLYCYLPHENYLALANYLGLYCYLSERYLVALYLGLUTAMINYLPHENYLALANYLALANYLGLYCYLPHENYLA LANINE MONOCLONAL ANTIBODY LYM 1 (1,4,7,10 TETRAAZACYCLODODECANE) 1,4,7,10 TETRAACETIC ACID IN 111; INDIUM 111; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CATABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CATHEPSINS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; LINEAR MODELS; LIVER; LYMPHOMA; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; PEPTIDES; RADIOIMMUNOTHERAPY; TIME FACTORS;

EID: 0141679544     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res., 48: 3270-3275, 1988.
2. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res., 43: 5347-5355, 1983.
3. Pimm, M. V., Perkins, A. C., and Baldwin, R. W. Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody. II. Biodistribution studies in mice with human tumor xenografts. Eur. J. Nucl. Med., 11: 300-304, 1985.
4. Deshpande, S. V., DeNardo, S. J., Kukis, D. L., Moi, M. K., McCall, M. J., DeNardo, G. L., and Meares, C. F. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med., 31: 473-479, 1990.
5. Mol, M. K., Meares, C. F., and DeNardo, S. J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane -N,N′,N″N‴ -tetraacetic acid and study of its yttrium (III) complex. J. Am. Chem. Soc., 110: 6266-6267, 1988.
6. Meares, C. F., Mol, M. K., Diril, H., Kukis, D. L., McCall, M. J., Shrikant, V., Deshpande, V., DeNardo, S. J., Snook, D., and Epenetos, A. A. Macrocyclic chelates of radiometals for diagnosis and therapy. Br. J. Cancer, 10: 21-26, 1990.
7. Larson, S. M., and Carrasquillo, J. A. Advantages of radioiodine over radioindium labeled monoclonal antibodies for imaging solid tumors. Nucl. Med. Biol., 15: 231-233, 1988.
8. Peterson, J. J., and Meares, C. F. Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Bioconjug. Chem., 10: 553-557, 1999.
9. Duncan, J. R., and Welch, M. J. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J. Nucl. Med., 34: 1728-1738, 1993.
10. 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anticarcinoembryonic antigen antibody. II. Comparative pharmacokinetics and biodistribution in human colorectal carcinoma-bearing nude mice. Nucl. Med. Biol., 20: 763-771, 1993.
11. Quadri, S. M., Vriesendorp, H. M., Leichner, P. K., and Williams, J. R. Evaluation of indium-111-and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J. Nucl. Med., 34: 938-945, 1993.
12. Gore, S., Morris, A. I., Gilmore, I. T., Maltby, P. J., Thornback, J. R., and Billington, D. Differences in the intracellular processing of the radiolabel following uptake of iodine-125 and technetium-99m-neogalactosyl albumin by the isolated perfused rat liver. J. Nucl. Med., 32: 506-512, 1991.
13. 111In-chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice. Eur. J. Nucl. Med., 12: 455-460, 1986.
14. Arano, Y., Wakisaka, K., Akizawa, H., Ono, M., Kawai, K., Nakayama, M., Sakahara, H., Konishi, J., and Saji, H. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery. Bioconjug. Chem., 9: 497-506, 1998.
15. Arano, Y., Wakisaka, K., Ohmono, Y., Uezono, T., Akizawa, H., Nakayama, M., Sakahara, H., Tanaka, C., Konishi, J., and Yokoyama, A. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: Evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for disgnostic and therapeutic applications. Bioconjug. Chem., 7: 628-637, 1996.
16. Studer, M., Kroger, L. A., DeNardo, S. J., Kukis, D. L., and Meares, C. F. Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA: comparison of enzymatic digestion in vitro and in vivo. Bioconjug. Chem., 3: 424-429, 1992.
17. Li, M., and Meares, C. F. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug. Chem., 4: 275-283, 1993.
18. DeNardo, G. L., Kroger, L. A., Meares, C. F., Richman, C. M., Salako, Q. A., Shen, S., Lamborn, K. R., Peterson, J. J., Miers, L. A., Zhong, G. R., and DeNardo, S. J. Comparison of 1,4,7,10-tetraazacyclododecaine-N,N′,N″ ,N‴-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin. Cancer Res., 4: 2483-2490, 1998.
19. DeNardo, S. J., Richman, C. M., Goldstein, D. S., Shen, S., Salako, Q. A., Kukis, D. L., Meares, C. F., Yuan, A., Welborn, J. L., and DeNardo, G. L. Yttrium-90/Indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res., 17: 1735-1744, 1997.
20. 20Y-linked monoclonal MUC-1 antibodies. Crit. Rev. Oncol. Hematol., 38: 26-35, 2001.
21. Peterson, J. J., and Meares, C. F. Cathepsin substrates as cleavable peptide linkers on bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug. Chem., 9: 618-626, 1998.
22. Lam, K. S., Salmon, S. E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., and Knapp, R. J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature (Lond.), 354: 82-84, 1991.
23. Lam, K. S. Application of combinatorial library methods in cancer research and drug discovery. Anticancer Drug Design, 12: 145-167, 1997.
24. Meldal, M., Svendsen, I., Breddam, K., and Auzanneau, F. I. Portion-mixing peptide libraries of quenched fluorogenic substrates for complete subsite mapping of endoprotease specificity. Proc. Natl. Acad. Sci. USA, 91: 3314-3318, 1994.
25. Lebl, M., Krchnak, V., Sepetov, N. F., Seligmann, B., Strop, P., Felder, S., and Lam, K. S. One-bead-one-structure combinatorial libraries. Biopolymers, 37: 177-198, 1995.
26. Liu, A. Y., Robinson, R. R., Hellström, K. E., Murray, E. D. J., Chang, C. P., and Hellström, I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA, 84: 3439-3443, 1987.
27. Fell, H. P., Gayle, M. A., Yelton, D., Lipsich, L., Schieven, G. L., Marken, J. S., Aruffo, A., Hellström, K. E., Hellström, I., and Bajorath, J. Chimeric L6 anti-tumor antibody: genomic construction, expression, and characterization of the antigen binding site. J. Biol. Chem., 267: 15552-15558, 1992.
28. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
29. McCall, M. J., Diril, H., and Meares, C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug. Chem., 1: 222-226, 1990.
30. 111indium-DOTA chelates: a simple and efficient method. Bioconjug. Chem., 5: 101-104, 1994.
31. 111Indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Cancer Res., 55 (Suppl): 5726s-5728s, 1995.
32. Beaumier, P. L., Neuzil, D., Yang, H. M., Noll, E. A., Kishore, R., Eary, J. F., Krohn, K. A., Nelp, W. B., Hellström, K. E., and Hellström, I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J. Nucl. Med., 27: 824-828, 1986.
33. DeNardo, S. J., Zhong, G.-R., Salako, Q., Li, M., DeNardo, G. L., and Meares, C. F. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J. Nucl. Med., 36: 829-836, 1995.
34. Govindarajulu, Z. Statistical techniques in bioassay. Karger, New York, 5-6, 1988.
35. Tsukuba, T., Okamoto, K., Yasuda, Y., Morikawa, W., Nakanishi, H., and Yamamoto, K. New functional aspects of cathepsin D and cathepsin E. Mol. Cells, 10: 601-611, 2000.
36. Conover, C. A., Perry, J. E., and Tindall, D. J. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab., 80: 987-993, 1995.
37. Trouet, A., Masquelier, M., Baurain, R., and Deprez-De Campeneere, D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 79: 626-629, 1982.
38. Deshpande, S. V., DeNardo, S. J., Meares, C. F., McCall, M. J., Adams, G. P., and DeNardo, G. L. Effect of different linkages between chelates and monoclonal antibodies on levels of radioactivity in the liver. Nucl. Med. Biol., 16: 587-597, 1989.
39. DeNardo, S. J., DeNardo, G. L., Yuan, A., Richman, C. M., O'Donnell, R. T., Lara, P. N., Kukis, D. L., Natarajan, A., Lamborn, K. R., Jacobs, F., Hartman-Siantar, C. L. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10 tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin. Cancer Res., 9 (Suppl.): 3938s-3944s, 2003.